These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37880985)

  • 1. Loss of the vitamin D receptor triggers senescence in chronic myeloid leukemia via DDIT4-mediated DNA damage.
    Xu Y; Qi W; Zheng C; Li Y; Lu Z; Guan J; Lu C; Zhao B
    J Mol Cell Biol; 2024 Apr; 15(10):. PubMed ID: 37880985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph
    Peter B; Eisenwort G; Sadovnik I; Bauer K; Willmann M; Rülicke T; Berger D; Stefanzl G; Greiner G; Hoermann G; Keller A; Wolf D; Čulen M; Winter GE; Hoffmann T; Schiefer AI; Sperr WR; Zuber J; Mayer J; Valent P
    Am J Hematol; 2022 Sep; 97(9):1215-1225. PubMed ID: 35794848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.
    Seman ZA; Ahid F; Kamaluddin NR; Sahid ENM; Esa E; Said SSM; Azman N; Mat WKDW; Abdullah J; Ali NA; Khalid MKNM; Yusoff YM
    BMC Res Notes; 2024 Apr; 17(1):111. PubMed ID: 38643202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel ABL1 mutation in a Moroccan CML patient with Imatinib resistance.
    El Bouchikhi I; Azami Idrissi H; Lazraq A; El Makhzen B; Ahakoud M; Berrady R; Ouldim K; Bouguenouch L; El-Azami-El-Idrissi M
    Cancer Genet; 2024 Nov; 288-289():40-42. PubMed ID: 39244947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.
    Ferrari-Amorotti G; Keeshan K; Zattoni M; Guerzoni C; Iotti G; Cattelani S; Donato NJ; Calabretta B
    Blood; 2006 Aug; 108(4):1353-62. PubMed ID: 16670262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.
    He N; Li G; Liu J; Liu W; Tian R; Ma D
    Front Immunol; 2024; 15():1452035. PubMed ID: 39635534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
    Coluccia AM; Vacca A; Duñach M; Mologni L; Redaelli S; Bustos VH; Benati D; Pinna LA; Gambacorti-Passerini C
    EMBO J; 2007 Mar; 26(5):1456-66. PubMed ID: 17318191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occurrence of Existing BCR-ABL Baseline Mutations and Associated Haplotype (NmR) Among CML Patients with Diverse IM Response: A Hospital-based Study from North-East India.
    Hazarika G; Kalita MJ; Das PP; Kalita S; Dutta K; Lahkar L; Rajkonwar A; Idris MG; Khamo V; Kusre G; Medhi S
    Biochem Genet; 2024 Dec; 62(6):4804-4816. PubMed ID: 38363412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance mutations in CML and how we approach them.
    Soverini S
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):469-475. PubMed ID: 38066920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
    Short NJ; Nguyen D; Jabbour E; Senapati J; Zeng Z; Issa GC; Abbas H; Nasnas C; Qiao W; Huang X; Borthakur G; Chien K; Haddad FG; Pemmaraju N; Karrar OS; Nguyen D; Konopleva M; Kantarjian H; Ravandi F
    Lancet Haematol; 2024 Nov; 11(11):e839-e849. PubMed ID: 39303729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells.
    Guerzoni C; Bardini M; Mariani SA; Ferrari-Amorotti G; Neviani P; Panno ML; Zhang Y; Martinez R; Perrotti D; Calabretta B
    Blood; 2006 May; 107(10):4080-9. PubMed ID: 16418324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.
    Notari M; Neviani P; Santhanam R; Blaser BW; Chang JS; Galietta A; Willis AE; Roy DC; Caligiuri MA; Marcucci G; Perrotti D
    Blood; 2006 Mar; 107(6):2507-16. PubMed ID: 16293596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.
    Chang JS; Santhanam R; Trotta R; Neviani P; Eiring AM; Briercheck E; Ronchetti M; Roy DC; Calabretta B; Caligiuri MA; Perrotti D
    Blood; 2007 Aug; 110(3):994-1003. PubMed ID: 17475908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring Inhibition Mechanisms in Wildtype and T315I BCR-ABL1: An In Silico Approach Integrating Virtual Screening, MD Simulations, and MM-GBSA Analysis.
    Balta O; Yilmaz E; Tatar Yilmaz G
    J Comput Chem; 2025 Jan; 46(1):e27545. PubMed ID: 39636243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy.
    Decroos A; Meddour S; Demoy M; Piccirilli N; Rousselot P; Nicolini FE; Ragot S; Gombert JM; Herbelin A; Barbarin A; Cayssials E
    Front Immunol; 2024; 15():1473139. PubMed ID: 39620210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vitamin D receptor is essential for the replication of pseudorabies virus.
    Zeng L; Wang S-Y; Du M-H; Chu B-B; Ming S-L
    mBio; 2024 Dec; 15(12):e0213724. PubMed ID: 39475231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Navigating diagnostic dilemmas: a rare presentation of extramedullary T-lymphoblastic leukemia/lymphoma with chronic myeloid leukemia.
    Alshomrani A; Laye R; Gupta N
    J Hematop; 2024 Dec; 17(4):275-279. PubMed ID: 39585574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.
    Bucelli C; Capodanno I; Miggiano MC; Cavazzini F; Crescenzi SL; Russo S; Carmosino I; Annunziata M; Sorà F; Bonifacio M; Luciano L; Caocci G; Loglisci G; Elena C; Lunghi F; Mullai R; Attolico I; Binotto G; Crisà E; Sportoletti P; Di Veroli A; Scortechini AR; Leporace AP; Maggi A; Crugnola M; Stagno F; Sancetta R; Murgano P; Rapezzi D; Luzi D; Vincelli DI; Galimberti S; Bocchia M; Fava C; Malato A; Abruzzese E; Saglio G; Specchia G; Breccia M; Iurlo A; Tiribelli M; Latagliata R
    Eur J Haematol; 2025 Jan; 114(1):37-44. PubMed ID: 39263855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computationally Driven Discovery of a BCR-ABL1 Kinase Inhibitor with Activity in Multidrug-Resistant Chronic Myeloid Leukemia.
    Hill J; Givhan RH; Yi B; Jones RM; Douglass EF; Xi Y; Schaefer HF; Crich D
    J Med Chem; 2024 Oct; 67(19):17820-17832. PubMed ID: 39311765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib induces cell apoptosis and increases the efficacy of αPD-1 in BCR::ABL T315I mutation CML by targeting UBE2Q1.
    Jiang F; Liu W; Zhou Y; Lin S; Zhang Q; Zhang W; Xue Y; Li C; Gao A; Shao M; Liao S; Ma T; Yu X
    Int Immunopharmacol; 2024 Dec; 143(Pt 2):113311. PubMed ID: 39454411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.